Published in Mol Psychiatry on May 01, 1998
Literature mining for the discovery of hidden connections between drugs, genes and diseases. PLoS Comput Biol (2010) 1.77
How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology (2008) 1.56
Is obsessive-compulsive disorder an autoimmune disease? CMAJ (2001) 1.48
Gene-environment interaction and the genetics of depression. J Psychiatry Neurosci (2004) 1.46
A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Neurosci (2012) 1.20
The disruption of Celf6, a gene identified by translational profiling of serotonergic neurons, results in autism-related behaviors. J Neurosci (2013) 1.05
Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter. Psychopharmacology (Berl) (2004) 1.01
Autism spectrum and obsessive-compulsive disorders: OC behaviors, phenotypes and genetics. Autism Res (2009) 0.96
The genetics of obsessive-compulsive disorder: a review. Dialogues Clin Neurosci (2010) 0.95
Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity. Philos Trans R Soc Lond B Biol Sci (2013) 0.94
Genetics of obsessive-compulsive disorder. Psychiatr Clin North Am (2010) 0.90
A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res (2010) 0.90
Serotonin transporter gene polymorphism and treatment response to serotonin reuptake inhibitor (escitalopram) in depression: An open pilot study. Indian J Psychiatry (2008) 0.86
The 5-HT7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorder. Neurosci Lett (2007) 0.83
Pharmacogenetics of anxiolytic drugs. J Neural Transm (Vienna) (2009) 0.83
SLC6A4 polymorphism, population genetics, and psychiatric traits. Hum Genet (2014) 0.82
Multi-cultural association of the serotonin transporter gene (SLC6A4) with substance use disorder. Neuropsychopharmacology (2013) 0.82
The role of the serotonergic and GABA system in translational approaches in drug discovery for anxiety disorders. Front Pharmacol (2013) 0.80
The genetic studies of obsessive-compulsive disorder and its future directions. Yonsei Med J (2006) 0.80
An integrated molecular landscape implicates the regulation of dendritic spine formation through insulin-related signalling in obsessive-compulsive disorder. J Psychiatry Neurosci (2016) 0.78
Functional Evaluations of Genes Disrupted in Patients with Tourette's Disorder. Front Psychiatry (2016) 0.76
Association of Anxiety Symptoms in Offspring of Bipolar Parents with Serotonin Transporter-Linked Polymorphic Region (5-HTTLPR) Genotype. J Child Adolesc Psychopharmacol (2015) 0.75
OCDB: a database collecting genes, miRNAs and drugs for obsessive-compulsive disorder. Database (Oxford) (2015) 0.75
Strain and sex based characterization of behavioral expressions in non-induced compulsive-like mice. Physiol Behav (2016) 0.75
Serotonin transporter gene polymorphisms & obsessive-compulsive disorder. Indian J Med Res (2010) 0.75
The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry (1989) 16.61
The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry (1989) 6.80
Report of the DNA committee and catalogs of cloned and mapped genes and DNA polymorphisms. Cytogenet Cell Genet (1989) 5.48
Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry (1990) 3.57
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry (2002) 3.01
A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry (2000) 2.48
Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med (1992) 2.39
Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry (1991) 2.17
A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry (1996) 2.04
Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry (1994) 2.04
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry (1998) 2.03
Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Am J Psychiatry (2000) 1.94
Family accommodation in obsessive-compulsive disorder. Am J Psychiatry (1995) 1.84
A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet (2001) 1.80
X-chromosome markers and manic-depressive illness. Rejection of linkage to Xq28 in nine bipolar pedigrees. Arch Gen Psychiatry (1990) 1.72
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry (1989) 1.66
Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry (1990) 1.56
Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry (1994) 1.56
Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry (1997) 1.54
Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry (2000) 1.54
Family accommodation of obsessive-compulsive symptoms: instrument development and assessment of family behavior. J Nerv Ment Dis (1999) 1.52
Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry (1995) 1.52
Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology (1998) 1.51
Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry (1992) 1.49
Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology (1992) 1.48
A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry (1998) 1.47
A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol (1991) 1.45
A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol Psychiatry (2000) 1.44
Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry (1996) 1.41
The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry (2007) 1.41
Rapid detoxification from opioid dependence. Am J Psychiatry (1989) 1.40
Linkage disequilibrium between an allele at the dopamine D4 receptor locus and Tourette syndrome, by the transmission-disequilibrium test. Am J Hum Genet (1996) 1.29
The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology (2001) 1.28
A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry (1995) 1.27
D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Mol Psychiatry (1998) 1.26
Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Arch Gen Psychiatry (1994) 1.22
Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry (1998) 1.19
Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry (1990) 1.17
Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet (1998) 1.16
Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry (1994) 1.16
Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology (Berl) (1993) 1.15
Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. Arch Gen Psychiatry (1994) 1.14
Gender differences in response to intranasal cocaine administration to humans. Biol Psychiatry (1996) 1.13
Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry (1995) 1.13
No association between ADCYAP1R1 and post-traumatic stress disorder in two independent samples. Mol Psychiatry (2011) 1.13
Cocaethylene: pharmacology, physiology and behavioral effects in humans. J Pharmacol Exp Ther (1995) 1.12
No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA (1994) 1.12
Insight and treatment outcome in obsessive-compulsive disorder. Compr Psychiatry (2001) 1.10
Population genetics of a functional variant of the dopamine beta-hydroxylase gene (DBH). Am J Med Genet (1997) 1.10
Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry (1997) 1.08
Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry (1990) 1.08
Intranasal oxytocin in obsessive-compulsive disorder. Biol Psychiatry (1996) 1.03
[123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry (1995) 1.03
Three cases of manic symptoms following yohimbine administration. Am J Psychiatry (1984) 1.03
Genetic polymorphism at the CLOCK gene locus and major depression. Am J Med Genet (2000) 1.02
Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Mol Psychiatry (2001) 1.02
Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol (1997) 1.01
The neurobiological correlates of childhood adversity and implications for treatment. Acta Psychiatr Scand (2013) 1.01
Corpus callosum dimensions measured by magnetic resonance imaging in bipolar affective disorder and schizophrenia. Biol Psychiatry (1989) 1.01
Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry (1999) 1.00
Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion. Mol Psychiatry (2002) 1.00
Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). Alcohol Clin Exp Res (1998) 0.98
The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Psychoneuroendocrinology (1994) 0.98
A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl) (1992) 0.97
Global functioning of inpatients with obsessive-compulsive disorder, schizophrenia, and major depression. Psychiatr Serv (1998) 0.96
Southeast Asian origins of five Hill Tribe populations and correlation of genetic to linguistic relationships inferred with genome-wide SNP data. Am J Phys Anthropol (2011) 0.95
The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry (1992) 0.95
Genetic influences of cortical gray matter in language-related regions in healthy controls and schizophrenia. Schizophr Res (2011) 0.95
Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse (1992) 0.95
Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol (1998) 0.95
Tryptophan hydroxylase genotype is associated with impulsive-aggression measures: a preliminary study. Am J Med Genet (1998) 0.92
Assessment of severity and change in obsessive compulsive disorder. Psychiatr Clin North Am (1992) 0.92
Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend (1990) 0.91
Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients. Am J Psychiatry (1997) 0.91
Temporal lobe measurement in primary affective disorder by magnetic resonance imaging. J Neuropsychiatry Clin Neurosci (1989) 0.91
Effects of acute tryptophan depletion on nocturnal melatonin secretion in humans. J Clin Endocrinol Metab (1993) 0.91
Dextromethorphan-induced psychosis. Am J Psychiatry (2000) 0.90
Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry (1988) 0.90
Treatment of clozapine-induced parotid gland swelling. Am J Psychiatry (1996) 0.90
Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull (1991) 0.90
Temperament and response to the Trier Social Stress Test. Acta Psychiatr Scand (2007) 0.89
Sertraline and breast-feeding. N Engl J Med (1997) 0.89
Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry (1999) 0.89
Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry (1997) 0.89
The pharmacotherapy of obsessive-compulsive disorder. Pharmacopsychiatry (1993) 0.89
The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis. Psychiatr Clin North Am (1993) 0.88
The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol (1993) 0.88
Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry (1994) 0.88
Obsessive-compulsive disorder with and without a chronic tic disorder. A comparison of symptoms in 70 patients. Br J Psychiatry (1994) 0.87
Exaggerated smooth muscle contraction segments on esophageal high-resolution manometry: prevalence and clinical relevance. Neurogastroenterol Motil (2014) 0.87
Support for association of RORA variant and post traumatic stress symptoms in a population-based study of hurricane exposed adults. Mol Psychiatry (2013) 0.87
Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. Life Sci (1989) 0.87
Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry (1986) 0.87